Current Phase 2 clinical studies involve Tetra’s BPN14770 and explore the potential cognitive benefit in a rare orphan disease, Fragile X Syndrome, and in Alzheimer’s Disease, a disease that affects upwards of 5 million elderly adults in the US. Human clinical trials play a key role in advancing science and moving us closer to discovering effective treatments for Fragile X Syndrome, Alzheimer’s Disease, traumatic brain injury, and schizophrenia.

How does BPN14770 differ from other drugs that have been tried for Alzheimer’s disease?

BPN14770 has a new mechanism of action. It differs from drugs that have been approved for the treatment of Alzheimer’s disease such as the cholinesterase inhibitors. Those drugs address a chemical imbalance that develops in mild-to-severe Alzheimer’s disease due to the loss of neurons that make a chemical known as acetylcholine.

In contrast, BPN14770 may be effective at earlier stages of Alzheimer’s disease by promoting the formation of new memories and by protecting connections between neurons that store old memories. In other words, BPN14770 may potentially delay the onset of Alzheimer’s disease by helping the brain retain its memory-making and keeping process.

How might BPN14770 help Fragile X Syndrome patients?

In Fragile X Syndrome, BPN14770 may help connections in the brain to mature, thereby improving brain function. Dr. Elizabeth Berry-Kravis explains the trial in this short video.

We welcome your interest in participating in a clinical trial.

For more general information about the progress we’re making in developing therapeutic products that treat brain disorders, follow us on Facebook and LinkedIn.

For technical information about Tetra’s clinical trials, clinicaltrials.gov provides detailed information about Fragile X Syndrome in Males age 18-45 and the Picasso AD Clinical Trial.